Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Tack Works Well in Dissection Repair of Complex Lesions: TOBA II BTK

News Conference News ISET 2024

Tack Works Well in Dissection Repair of Complex Lesions: TOBA II BTK

January 25, 2024

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

PAD Care on the Backdrop of Cancer Requires Creativity, Persistence

News Conference News ISET 2020

PAD Care on the Backdrop of Cancer Requires Creativity, Persistence

January 23, 2020

News Conference News VEITH 2019

Endovascular Office-Based Labs: Balancing Upsides Against Potential for Abuse

November 28, 2019

Two Small Series Support Role for Cerebral Protection in TAVR

News Conference News PCR London Valves 2019

Two Small Series Support Role for Cerebral Protection in TAVR

Michael O'Riordan

November 18, 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

Mechanical Thrombectomy Outcomes May Be Worse at Low-Volume Stroke Centers

News Conference News ISC 2019

Mechanical Thrombectomy Outcomes May Be Worse at Low-Volume Stroke Centers

February 07, 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

January 29, 2019

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

September 22, 2018

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis with Few Complications

News Conference News The Structural Heart Disease Summit 2018

SAFE-MANTA: Large-Bore Vascular Closure Device Achieves Fast Hemostasis With Few Complications

Michael O'Riordan

June 23, 2018

Next-Generation Large-Bore Closure Devices Arrive

News Conference News ISET 2018

Next-Generation Large-Bore Closure Devices Arrive

February 05, 2018

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

October 20, 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

March 23, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Definitive Trials Spur Sharp Uptick in Use of Endovascular Therapy for Acute Ischemic Stroke

News Conference News ISC 2017

Definitive Trials Spur Sharp Uptick in Use of Endovascular Therapy for Acute Ischemic Stroke

March 02, 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

February 17, 2017

News Conference News AHA 2016

AHA/ACC Issue Updated PAD Guidelines

November 14, 2016

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

November 09, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.